Veterinary Compounded Medication Quality and Safety Regulatory Vacuum

Compounding pharmacies that prepare custom veterinary medications — such as flavored liquid formulations of drugs that only exist in tablet form for humans — operate without FDA manufacturing oversight, are not required to register with the FDA, face no mandatory adverse event reporting requirements, and have no obligation to demonstrate drug stability, potency, or sterility for animal-specific preparations. So what? Independent studies have repeatedly shown that compounded veterinary medications frequently fail potency testing, meaning a cat receiving compounded methimazole for hyperthyroidism may be getting 50% or 200% of the intended dose, with no way for the prescribing veterinarian or owner to know. So what? Under-dosing leads to therapeutic failure and disease progression, while over-dosing causes toxicity — and because adverse event reporting is not required, these failures go undetected at the population level, preventing regulators from identifying dangerous compounders. So what? Since 2001, only 62 compound-related adverse events in animals have been reported to the FDA, a number that is almost certainly a gross undercount given the volume of compounded prescriptions dispensed. So what? Veterinarians who prescribe compounded medications cannot evaluate compounder quality because there is no publicly accessible quality rating system, no mandatory testing results disclosure, and state boards of pharmacy are often prevented by privacy laws from sharing adverse event data about veterinary compounds. So what? The regulatory vacuum creates a two-tier system where well-resourced veterinary hospitals use PCAB-accredited compounding pharmacies while cost-sensitive clinics and pet owners use unaccredited compounders of unknown quality, with no transparency to distinguish between them. Structural root cause: The FDA's authority over compounded animal drugs sits in a jurisdictional gray zone between the Federal Food, Drug, and Cosmetic Act and state pharmacy boards, and the FDA has chosen enforcement discretion rather than rulemaking, meaning the regulatory framework is defined by guidance documents that carry no force of law and change unpredictably.